Skip to main content

Table 4 BRAF mutation and KRAS mutation rates according to CIMP and MSI status

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

  Present study Lee et al. [27] Weisenberger et al. [20] Ogino et al. [37] Kambara et al. [36]
  BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%)
CIMP-low/negative 0.9 34.1 1.1 31.5 1.3 35.4 6.2 41.6 10.3 37.2
CIMP-high 26.5 35.3 11.9 38.1 72.7 9.7 61.2 7.5 76.9 15.4
MSI-low/MSS 2.6 35.7 3.4     8.9 41.3 8.6 44.4
MSI-high 12.2 28.6 10.5     48.6 10.0 76.1 2.2
  1. CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stable